[
  {
    "ts": "2025-10-15T12:00:00+00:00",
    "headline": "Newleos Therapeutics CEO David Donabedian Recognized by Goldman Sachs as One of the Most Exceptional Entrepreneurs at the 2025 Builders and Innovators Summit",
    "summary": "BOSTON, October 15, 2025--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that Goldman Sachs (NYSE:GS) is recognizing David H. Donabedian, Ph.D., Newleos’ Founding Chief Executive Officer and Executive Partner at Longwood Fund, as one of the Most Exceptional Entrepreneurs of 2025 at its Builders and Innovators Summit in Healdsburg, California.",
    "url": "https://finance.yahoo.com/news/newleos-therapeutics-ceo-david-donabedian-120000027.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "69c59617-6f6b-34b5-ad17-e72c4602e234",
      "content": {
        "id": "69c59617-6f6b-34b5-ad17-e72c4602e234",
        "contentType": "STORY",
        "title": "Newleos Therapeutics CEO David Donabedian Recognized by Goldman Sachs as One of the Most Exceptional Entrepreneurs at the 2025 Builders and Innovators Summit",
        "description": "",
        "summary": "BOSTON, October 15, 2025--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that Goldman Sachs (NYSE:GS) is recognizing David H. Donabedian, Ph.D., Newleos’ Founding Chief Executive Officer and Executive Partner at Longwood Fund, as one of the Most Exceptional Entrepreneurs of 2025 at its Builders and Innovators Summit in Healdsburg, California.",
        "pubDate": "2025-10-15T12:00:00Z",
        "displayTime": "2025-10-15T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a555a0bfa6459bd96475d376c650c57b",
          "originalWidth": 850,
          "originalHeight": 350,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CGzIFDEyQ54d51lFzbjfvQ--~B/aD0zNTA7dz04NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a555a0bfa6459bd96475d376c650c57b.cf.webp",
              "width": 850,
              "height": 350,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xCqCiMZjBEaKhhkWHCVTvg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a555a0bfa6459bd96475d376c650c57b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/newleos-therapeutics-ceo-david-donabedian-120000027.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/newleos-therapeutics-ceo-david-donabedian-120000027.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GS"
            },
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]